‎First Guidance on Deprescribing Stimulants in Adult ADHD

 ADHD in the News 2026-05-28


An expert panel has released the first formal guidance on deprescribing stimulant medications in adults with attention-deficit/ hyperactivity disorder, recommendations that come as US stimulant prescribing increased by more than 50% over the past decade with little to no direction on when treatment should be tapered or stopped. The consensus statement, developed by an American Society of Clinical Psychopharmacology (ASCP) international task force of 45 psychopharmacology experts, identifies clinical scenarios in which deprescribing warrants consideration, organized into three categories: inadequate efficacy, associated harm, and misuse.  It was published online May 20 in European Neuropsychopharmacology.

View Article: Medscape, May 27, 2026




Other Articles in this Edition

‎First Guidance on Deprescribing Stimulants in Adult ADHD

Global mental disorders have nearly doubled since 1990, now affecting 1.2 billion people worldwide

Girls with ADHD from deprived backgrounds may face a higher risk of long-term health conditions

When ADHD Goes Viral: Social Media and Misinformation (Commentary) 

Rethinking ADHD: Brain scans indicate at least 3 subtypes attention-deficit/hyperactivity disorder 

I have ADHD. It’s not a deficit for me, it’s a lever. | Your Turn (Opinion)

When Therapy Misreads Neurodivergent Clients 

Mental Health Apps for Students Are Growing. Here’s What Schools Need to Know

The Neurocognitive Roots of Boredom in ADHD: a Meta-Analysis 

A new AI tool spots hidden signs of adult ADHD months before a formal diagnosis 

Case of mistaken patterns: Slow brain development linked to ADHD for years might just be sex differences

Brain development patterns predict if childhood ADHD symptoms will fade or persist 

Prenatal air pollution linked to ADHD symptoms in school-age children, but not clinical diagnosis